Literature DB >> 11223164

Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells.

N Chattopadhyay1, R R Butters, E M Brown.   

Abstract

Retinoids participate in the onset of differentiation, apoptosis and the inhibition of growth in a wide variety of normal and cancerous cells. Several recent reports have shown that hepatocyte growth factor (HGF), and its receptor, c-Met, are expressed at abnormally high levels in various human malignant gliomas and exert a strong proliferative action in an autocrine fashion. These results, consequently, imply that HGF and its receptor may represent a major contributor to the progression of such malignancies. Since astrocytomas are the most frequently occurring glioma, we have shown here that U87 cells - a well-established, human astrocytoma cell line - express both HGF and c-Met, thereby providing a suitable astrocytic tumor model for studying the potential role of HGF, functioning in an autocrine mode, in astrocytic tumorigenesis. Furthermore, we demonstrated the expression of the retinoic acid receptor (RAR) isoforms, RARalpha, -beta and -gamma, as well as the retinoid x-receptor (RxR) isoforms, RxRalpha and -beta, by RT-PCR and western blot analysis in these cells. Since ligands of the RARs and RxRs are known to exert growth inhibitory effects on various tumor cells which include some astrocytomas, we speculated that such effect of retinoids might be mediated via inhibition of HGF secretion in human astrocytoma cells. Indeed, we have shown that the RAR agonists, all-trans retinoic acid (ATRA) and (E)-4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid (TTNPB), inhibited HGF secretion with half maximal inhibition occurring at 3.0 microM and 15 nM, respectively, as did the RxR agonists, 9-cis- and 13-cis retinoic acid (9cRA and 13cRA, respectively), which exerted half-maximal inhibitory effects at 40 and 25 nM, respectively. These actions of the RAR and RxR agonists appear to be exerted at the transcriptional level as assessed by Northern blot analysis. Taken together, our results show for the first time that retinoids, acting via the RAR and RxRs, significantly inhibit both the secretion and expression of HGF, thereby interrupting a potentially highly tumorigenic autocrine loop in astrocytoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223164     DOI: 10.1016/s0165-3806(00)00154-1

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

1.  Molecular imaging of c-Met tyrosine kinase activity.

Authors:  Limin Zhang; Shama Virani; Yu Zhang; Mahaveer S Bhojani; Teresa L Burgess; Angela Coxon; Craig J Galban; Brian D Ross; Alnawaz Rehemtulla
Journal:  Anal Biochem       Date:  2011-01-27       Impact factor: 3.365

2.  Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

Authors:  V A Levin; P Giglio; V K Puduvalli; J Jochec; M D Groves; W K A Yung; K Hess
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

3.  Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Authors:  Elisa Vigna; Giovanni Pacchiana; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Paolo Michieli; Paolo M Comoglio
Journal:  J Mol Med (Berl)       Date:  2013-09-07       Impact factor: 4.599

4.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

Authors:  Siew-Ju See; Victor A Levin; W-K Alfred Yung; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

5.  Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Authors:  Caecilia Wismeth; Peter Hau; Klaus Fabel; Ulrike Baumgart; Birgit Hirschmann; Horst Koch; Tanja Jauch; Oliver Grauer; Lisa Drechsel; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

6.  Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells.

Authors:  Sheng-hua Chu; Yan-bin Ma; Hong Zhang; Dong-fu Feng; Zhi-an Zhu; Zhi-qiang Li; Xian-hou Yuan
Journal:  J Neurooncol       Date:  2007-04-27       Impact factor: 4.130

7.  Inhibition of all-trans retinoic acid on MDM2 gene expression in astrocytoma cell line SHG-44.

Authors:  Yi Zeng; Zhong Yang; Xiao-Dong Long; Chao You
Journal:  Neurosci Bull       Date:  2008-10       Impact factor: 5.203

8.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.

Authors:  Paul H Huang; Akitake Mukasa; Rudy Bonavia; Ryan A Flynn; Zachary E Brewer; Webster K Cavenee; Frank B Furnari; Forest M White
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

Review 9.  Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.

Authors:  Danijela Drakulic; Marija Schwirtlich; Isidora Petrovic; Marija Mojsin; Milena Milivojevic; Natasa Kovacevic-Grujicic; Milena Stevanovic
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.